Pipeline
ABL602
HomePipelineABL602
-
- Pipeline
- ABL602
-
- Program Target
- CLL1xCD3
-
- Disease Indication
- Blood Cancer
-
- Development Stage
- IND enabling study
- Summary
- ABL602 is a head-to-tail 2+1 bispecific T cell engager targeting CLL1. ABL602 binds weakly to CD3 in normal tissue, but its binding is greatly potentiated in tumor microenvironments (TME). ABL602 exhibits anti-tumor activity via CLL1 mediated T cell activation and does not induces cytokines in the absence of CLL1. ABL602 is expected to be a safer and more effective therapy for AML.
